Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Goldman

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Seminars in Hematology|February 4, 2003
Chronic myeloid leukemia--past, present, and futureJohn Goldman
Current Opinion in Hematology|December 18, 2004
Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib eraJohn Goldman
The Hematology Journal : the Official Journal of the European Haematology Association|April 18, 2002
A new impetus for The Hematology JournalJohn Goldman
Nature Clinical Practice. Oncology|November 3, 2005
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?John Goldman
Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology|November 6, 2004
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?John Goldman
Leukemia & Lymphoma|December 11, 2007
Chronic myeloid leukemia--therapy in the 20th and 21st centuriesJohn Goldman
Leukemia & Lymphoma|December 3, 2005
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?John Goldman, Myrtle Gordon
Leukemia & Lymphoma|December 11, 2007
Obituary. David Abraham Goitein GaltonBarbara Bain, Daniel Catovsky, John Goldman
Idcases|March 4, 2020
Emerging pathogens: A case of <i>Wohlfahrtiimonas chitiniclastica</i> and <i>Ignatzschineria indica</i> bacteremiaSamantha Snyder, Pratiksha Singh, John Goldman
The Journal of Clinical Investigation|July 2, 2010
Chronic myeloid leukemia: mechanisms of blastic transformationDanilo Perrotti, Catriona Jamieson, John Goldman, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Seminars in Hematology|February 4, 2003
Chronic myeloid leukemia--past, present, and futureJohn Goldman
Current Opinion in Hematology|December 18, 2004
Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib eraJohn Goldman
The Hematology Journal : the Official Journal of the European Haematology Association|April 18, 2002
A new impetus for The Hematology JournalJohn Goldman
Nature Clinical Practice. Oncology|November 3, 2005
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?John Goldman
Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology|November 6, 2004
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?John Goldman
Leukemia & Lymphoma|December 11, 2007
Chronic myeloid leukemia--therapy in the 20th and 21st centuriesJohn Goldman
Leukemia & Lymphoma|December 3, 2005
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?John Goldman, Myrtle Gordon
Leukemia & Lymphoma|December 11, 2007
Obituary. David Abraham Goitein GaltonBarbara Bain, Daniel Catovsky, John Goldman
Idcases|March 4, 2020
Emerging pathogens: A case of <i>Wohlfahrtiimonas chitiniclastica</i> and <i>Ignatzschineria indica</i> bacteremiaSamantha Snyder, Pratiksha Singh, John Goldman
The Journal of Clinical Investigation|July 2, 2010
Chronic myeloid leukemia: mechanisms of blastic transformationDanilo Perrotti, Catriona Jamieson, John Goldman, et al.
Pageof 6